Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study.

被引：3
|
作者：
Powles, Thomas
Albiges, Laurence
Jalkanen, Katriina Johanna
De Velasco, Guillermo
Burotto, Mauricio
Ghatalia, Pooja
Suarez, Cristina
Lam, Elaine T.
Iacovelli, Roberto
Gumus, Mahmut
Verzoni, Elena
Kollmannsberger, Christian K.
Stadler, Walter Michael
Venugopal, Balaji
Shinde, Reshma
Saretsky, Todd L.
He, Li
Vickery, Donna
Choueiri, Toni K.
Rini, Brian I.
机构：
[1] Queen Mary Univ London, Barts Canc Inst, Canc Res UK Expt Canc Med Ctr, London, England
[2] Univ Paris Saclay, Gustave Roussy, Paris, France
[3] Helsinki Univ Hosp, Helsinki, Finland
[4] 12 Octubre Univ Hosp, Med Oncol Dept, Madrid, Spain
[5] Bradford Hill Clin Res Ctr, Santiago, Chile
[6] Fox Chase Canc Ctr, Philadelphia, PA USA
[7] Hosp Univ Vall dHebron, Vall dHebron Barcelona Hosp Campus, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[8] Univ Colorado, Canc Ctr, Aurora, CO USA
[9] Fdn Policlin Univ A Gemelli, IRCCS, Rome, Italy
[10] Istanbul Medeniyet Univ, Goztepe Prof Dr Suleyman Yalcin City Hosp, Istanbul, Turkiye
[11] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[12] BC Canc Vancouver Canc Ctr, Vancouver, BC, Canada
[13] Univ Chicago, Chicago, IL USA
[14] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Scotland
[15] Merck & Co Inc, Rahway, NJ USA
[16] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA
[17] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.4_suppl.361
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
361
引用
收藏
页码：361 / 361
页数：1
相关论文
共 50 条
  • [31] CheckMate 025: a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC)
    Motzer, Robert J.
    Escudier, Bernard
    Mcdermott, David F.
    George, Saby
    Hammers, Hans J.
    Srinivas, Sandhya
    Tykodi, Scott S.
    Sosman, Jeffrey A.
    Procopio, Giuseppe
    Plimack, Elizabeth R.
    Castellano, Daniel
    Gurney, Howard
    Donskov, Frede
    Bono, Petri
    Wagstaff, John
    Gauler, Thomas C.
    Ueda, Takeshi
    Xu, Li-An
    Waxman, Ian M.
    Sharma, Padmanee
    BJU INTERNATIONAL, 2015, 116 : 17 - 17
  • [32] Patient-reported outcomes (PROs) in ASCEND-5: A randomized, phase 3 study of ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase rearranged (ALK plus ) NSCLC previously treated with CT and crizotinib (CRZ)
    Mok, T. S. K.
    Scagliotti, G.
    Kim, T. M.
    Crino, L.
    Liu, G.
    Gridelli, C.
    Novello, S.
    Kiura, K.
    Bearz, A.
    Gautschi, O.
    Felip, E.
    Nishio, M.
    Spigel, D. R.
    Urban, P.
    Deudon, S.
    Zheng, C.
    Shaw, A. T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [33] Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a firstline treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).
    Motzer, Robert J.
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Grunwald, Viktor
    Hutson, Thomas E.
    Alekseev, Boris
    Rha, Sun Young
    Kopyltsov, Evgeny
    Mendez Vidal, Maria Jose
    Hong, Sung-Hoo
    Kapoor, Anil
    Gordoa, Teresa Alonso
    Goh, Jeffrey C.
    Merchan, Jaime R.
    Smith, Alan D.
    Mody, Kalgi
    Perini, Rodolfo F.
    Xing Dongyuan
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [34] Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
    Powles, Thomas
    Motzer, Robert J.
    Escudier, Bernard
    Par, Sumanta
    Kollmannsberger, Christian
    Pikiel, Joanna
    Gurney, Howard
    Rha, Sun Young
    Park, Se Hoon
    Geertsen, Poul F.
    Gross-Goupil, Marine
    Grande, Enrique
    Suarez, Cristina
    Markby, David W.
    Arroyo, Alan
    Dean, Mark
    Choueiri, Toni K.
    George, Daniel
    BRITISH JOURNAL OF CANCER, 2018, 119 (06) : 663 - 669
  • [35] Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
    Thomas Powles
    Robert J. Motzer
    Bernard Escudier
    Sumanta Pal
    Christian Kollmannsberger
    Joanna Pikiel
    Howard Gurney
    Sun Young Rha
    Se Hoon Park
    Poul F. Geertsen
    Marine Gross-Goupil
    Enrique Grande
    Cristina Suarez
    David W. Markby
    Alan Arroyo
    Mark Dean
    Toni K. Choueiri
    Daniel George
    British Journal of Cancer, 2018, 119 : 663 - 669
  • [36] Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial (vol 20, pg 297, 2019)
    Cella, D.
    Grunwald, V
    Escudier, B.
    LANCET ONCOLOGY, 2019, 20 (06): : E293 - E293
  • [37] Outcomes based on age in the phase 3 Meteor trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC)
    Bergmann, L.
    Donskov, F.
    Motzer, R. J.
    Voog, E.
    Hovey, E. J.
    Gruellich, C.
    Nott, L. M.
    Cuff, K. E.
    Gil, T.
    Jensen, N., V
    Chevreau, C.
    Negrier, S.
    Depenbusch, R.
    Cornelio, I
    Champsaur, A.
    Escudier, B. J.
    Pal, S. K.
    Powles, T.
    Choueiri, T. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 200 - 201
  • [38] Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC).
    Donskov, Frede
    Motzer, Robert J.
    Voog, Eric
    Hovey, Elizabeth J.
    Griillich, Carsten
    Nott, Louise M.
    Cuff, Katharine Ellen
    Gil, Thierry
    Jensen, Niels Viggo
    Chevreau, Christine
    Negrier, Sylvie
    Depenbusch, Reinhard
    Bergmann, Lothar
    Cornelio, Izzy
    Champsaur, Anne
    Escudier, Bernard J.
    Pal, Sumanta K.
    Powles, Thomas
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] Patient-reported outcomes in elderly vs. young patients with advanced renal cell carcinoma treated with sorafenib vs. placebo
    Shah, S.
    Cella, D.
    Gondek, K.
    Cihon, F.
    Anderson, S.
    VALUE IN HEALTH, 2008, 11 (03) : A79 - A79
  • [40] Phase II study of sequential first-line pazopanib (PAZ) followed by everolimus (EVE) in patients (pts) with advanced or metastatic renal cell carcinoma (RCC) (CATChEz Study).
    de Souza, Paul L.
    Wong, Shirley
    Sewak, Sanjeev
    Kotasek, Dusan
    Keam, Bhumsuk
    Chung, Jinsoo
    Erbeck, Noelle
    Han, Jackie
    Dezzani, Luca
    Ahmad, Qasim
    Mainwaring, Paul N.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
12345